دورية أكاديمية
(R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders
| العنوان: | (R)-(-)-Ketamine: The Promise of a Novel Treatment for Psychiatric and Neurological Disorders |
|---|---|
| المؤلفون: | Hana Shafique, Julie C. Demers, Julia Biesiada, Lalit K. Golani, Rok Cerne, Jodi L. Smith, Marta Szostak, Jeffrey M. Witkin |
| المصدر: | International Journal of Molecular Sciences, Vol 25, Iss 12, p 6804 (2024) |
| بيانات النشر: | MDPI AG, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Biology (General) LCC:Chemistry |
| مصطلحات موضوعية: | major depressive disorder, rapid-acting antidepressant, inflammation, ketamine, (R)-ketamine, substance use disorder, Biology (General), QH301-705.5, Chemistry, QD1-999 |
| الوصف: | NMDA receptor antagonists have potential for therapeutics in neurological and psychiatric diseases, including neurodegenerative diseases, epilepsy, traumatic brain injury, substance abuse disorder (SUD), and major depressive disorder (MDD). (S)-ketamine was the first of a novel class of antidepressants, rapid-acting antidepressants, to be approved for medical use. The stereoisomer, (R)-ketamine (arketamine), is currently under development for treatment-resistant depression (TRD). The compound has demonstrated efficacy in multiple animal models. Two clinical studies disclosed efficacy in TRD and bipolar depression. A study by the drug sponsor recently failed to reach a priori clinical endpoints but post hoc analysis revealed efficacy. The clinical value of (R)-ketamine is supported by experimental data in humans and rodents, showing that it is less sedating, does not produce marked psychotomimetic or dissociative effects, has less abuse potential than (S)-ketamine, and produces efficacy in animal models of a range of neurological and psychiatric disorders. The mechanisms of action of the antidepressant effects of (R)-ketamine are hypothesized to be due to NMDA receptor antagonism and/or non-NMDA receptor mechanisms. We suggest that further clinical experimentation with (R)-ketamine will create novel and improved medicines for some of the neurological and psychiatric disorders that are underserved by current medications. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1422-0067 1661-6596 |
| Relation: | https://www.mdpi.com/1422-0067/25/12/6804; https://doaj.org/toc/1661-6596; https://doaj.org/toc/1422-0067 |
| DOI: | 10.3390/ijms25126804 |
| URL الوصول: | https://doaj.org/article/94ab1d8cc61948f5a50dff7a0f651876 |
| رقم الأكسشن: | edsdoj.94ab1d8cc61948f5a50dff7a0f651876 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14220067 16616596 |
|---|---|
| DOI: | 10.3390/ijms25126804 |